Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | LPL | P06858 | 9/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA3 | P07451 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16076006 | 0.80 | FFAR1 (0.38) | FFAR1LPLLIPGDGAT1CA1 | |
| SCHEMBL2067804 | 0.80 | LPL (0.45) | FFAR1LPLLIPGDGAT1CA1 | |
| SCHEMBL15536053 | 0.80 | DGAT1 (0.45) | FFAR1LPLLIPGDGAT1CA1 | |
| SCHEMBL28990423 | 0.80 | LPL (0.41) | FFAR1LPLLIPGDGAT1CA1 | |
| SCHEMBL30059627 | 0.78 | DGAT1 (0.46) | LPLLIPGDGAT1CA1CA2 | |
| SCHEMBL182754 | 0.78 | DGAT1 (0.46) | LPLLIPGDGAT1CA1CA2 | |
| SCHEMBL1284338 | 0.78 | LPL (0.42) | FFAR1LPLLIPGDGAT1CA1 | |
| SCHEMBL15716443 | 0.78 | ROCK2 (0.47) | FFAR1LPLLIPGDGAT1ROCK2 | |
| SCHEMBL20896372 | 0.78 | DGAT1 (0.43) | FFAR1LPLLIPGDGAT1CA1 | |
| SCHEMBL20896845 | 0.78 | CA1 (0.45) | FFAR1LPLLIPGDGAT1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590080-B2 | Compounds | PAKINAX PTY LTD. (AU) | 2026-03-31 | — | — | US | disclosed |
| US-20250230169-A1 | Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety | CURIS INC (US) | 2025-07-17 | — | — | US | disclosed |
| US-20250115598-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-04-10 | — | — | US | disclosed |
| US-20250059188-A1 | ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-02-20 | — | — | US | disclosed |
| US-20250051341-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPESVIRUSES | MERCK SHARP & DOHME LLC (US) | 2025-02-13 | — | — | US | disclosed |
| US-20240368104-A1 | Novel Dialkoxynaphtho[2,3-C]Furan-1(3H)-One Derivatives and Pharmaceutical Composition For Preventing or Treating Respiratory Disease or SARS-COV-2 Infection Disease, Comprising Same | DONG WHA PHARM. CO., LTD. (KR) | 2024-11-07 | — | — | US | disclosed |
| EP-4447971-A2 | PYRAZOLOPYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPESVIRUSES | Merck Sharp & Dohme LLC (US) | 2024-10-23 | — | — | EP | disclosed |
| CN-115054600-B | Aromatic sulfonamide derivatives | 拜耳制药股份公司 | 2024-06-14 | — | — | CN | disclosed |
| US-12006316-B2 | 9H-pyrrolo-dipyridine derivatives | UCB Biopharma SRL (BE) | 2024-06-11 | — | — | US | disclosed |
| EP-4352059-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | Incyte Corporation (US) | 2024-04-17 | — | — | EP | disclosed |
| EP-1984350-B1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-08-18 | — | — | EP | disclosed |
| EP-1984350-B1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-08-18 | — | — | EP | disclosed |
| WO-2010080996-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| US-20100130492-A1 | MORPHOLINOPURINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20100130492-A1 | MORPHOLINOPURINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20100130492-A1 | MORPHOLINOPURINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| WO-2009093981-A1 | TRIAZINE COMPOUNDS AS KINASE INHIBITORS | S BIO PTE LTD (SG) | 2009-07-30 | — | — | WO | disclosed |
| EP-1984350-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | Novartis AG (CH) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007084786-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007084786-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051341-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPESVIRUSES | TYMP, TPMT, DPYD | FFAR1 4337/4885LPL 4453/4885LIPG 3598/4885 |
| US-20240368104-A1 | Novel Dialkoxynaphtho[2,3-C]Furan-1(3H)-One Derivatives and Pharmaceutical Composition For Preventing or Treating Respiratory Disease or SARS-COV-2 Infection Disease, Comprising Same | IL5, ACE2, IL15 | FFAR1 573/4885LPL 3407/4885LIPG 3149/4885 |
| US-20250230169-A1 | Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety | BAZ2A, BAZ2B, PI4KB | FFAR1 3493/4885LPL 1525/4885LIPG 1712/4885 |
| US-20250115598-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | MLKL, CASP1, CASP9 | FFAR1 1395/4885LPL 1442/4885LIPG 1293/4885 |
| US-12590080-B2 | Compounds | PAK4, PAK2, PAK1 | FFAR1 1842/4885LPL 3590/4885LIPG 4130/4885 |
| US-12006316-B2 | 9H-pyrrolo-dipyridine derivatives | MAPT, PSEN1, PRNP | FFAR1 4243/4885LPL 4101/4885LIPG 4343/4885 |
| US-20100130492-A1 | MORPHOLINOPURINE DERIVATIVES | MTOR, RICTOR, PIK3R1 | FFAR1 3462/4885LPL 4668/4885LIPG 4859/4885 |
| US-20250059188-A1 | ARYLSULPHONAMIDE COMPOUNDS | MLKL, CASP1, CASP9 | FFAR1 950/4885LPL 1381/4885LIPG 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.